MetaVia Inc. (MTVA)vsNovartis AG ADR (NVS)
MTVA
MetaVia Inc.
$1.58
-1.11%
HEALTHCARE · Cap: $7.64M
NVS
Novartis AG ADR
$155.49
+0.99%
HEALTHCARE · Cap: $296.54B
Smart Verdict
WallStSmart Research — data-driven comparison
NVS leads profitability with a 23.9% profit margin vs 0.0%. NVS earns a higher WallStSmart Score of 49/100 (D+).
MTVA
Avoid26
out of 100
Grade: F
NVS
Hold49
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for MTVA.
Margin of Safety
-74.2%
Fair Value
$91.79
Current Price
$155.49
$63.70 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Reasonable price relative to book value
Conservative balance sheet, low leverage
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Areas to Watch
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Grey zone — moderate risk
Elevated debt levels
Expensive relative to growth rate
Revenue declined 0.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : MTVA
The strongest argument for MTVA centers on Price/Book, Debt/Equity.
Bull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bear Case : MTVA
The primary concerns for MTVA are Revenue Growth, EPS Growth, Market Cap.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, Debt/Equity, PEG Ratio.
Key Dynamics to Monitor
MTVA profiles as a value stock while NVS is a declining play — different risk/reward profiles.
MTVA carries more volatility with a beta of 0.97 — expect wider price swings.
MTVA is growing revenue faster at 0.0% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (49/100 vs 26/100), backed by strong 23.9% margins. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
MetaVia Inc.
HEALTHCARE · BIOTECHNOLOGY · USA
MetaVia Inc. is a forward-thinking technology firm specializing in transformative digital solutions that optimize connectivity and productivity across various sectors. By harnessing state-of-the-art artificial intelligence and cloud computing, MetaVia develops robust, customized platforms designed to address the unique challenges of its clientele. With a strong commitment to sustainability and social responsibility, the company not only meets current market expectations but also fosters long-term growth potential. Positioned strategically to capitalize on evolving trends in the tech industry, MetaVia aims to deliver substantial value to its shareholders while adapting to an ever-changing landscape.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?